FDA.reportPublic FDA data

bevacizumab-bvzr 400 MG per 16 ML Injection

RxCUI
2268047
RxNorm name
bevacizumab-bvzr 400 MG per 16 ML Injection
Display name
bevacizumab-bvzr 400 MG per 16 ML Injection
Full name
bevacizumab-bvzr 400 MG per 16 ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:14

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761099Zirabevbevacizumab-bvzr351(k) BiosimilarRx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ZirabevBEVACIZUMAB-BVZRPfizer Laboratories Div Pfizer Incaa27acbd-d117-4350-aeee-17bc2e2c0ca42026-07-21Warnings, Adverse reactionsExact identifier
rxcui: 2268047

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
aa27acbd-d117-4350-aeee-17bc2e2c0ca4bevacizumab-bvzr 400 MG in 16 ML Injection [PSN] · 16 ML bevacizumab-bvzr 25 MG/ML Injection [SCD] · bevacizumab-bvzr 25 MG/ML per 16 ML Injection [SY] · bevacizumab-bvzr 400 MG per 16 ML Injection [SY]412These highlights do not include all the information needed to use ZIRABEV safely and effectively. See full prescribing information for ZIRABEV. ZIRABEV™ (bevacizumab-bvzr) injection, for intravenous use Initial U.S. Approval: 2019 ZIRABEV (bevacizumab-bvzr) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betw20250805